Clinical value is not commercial value.

That is the subject of this week’s HealthVC newsletter.

A healthtech company can have strong evidence, credible clinical validation, respected physicians behind it, and a pilot inside a serious healthcare organization.

And still fail commercially.

This is where many founders misunderstand the market. Clinical validation gives you the right to enter the commercial conversation. It does not close the sale.

Hospitals, payers, pharma, and providers do not adopt because a product is better in theory. They adopt when the product can move through the machinery of budgets, workflows, procurement, implementation, reimbursement, compliance, and internal decision-making.

That machinery is where many promising companies get stuck.

A pilot is not an adoption.

A champion is not a buyer.

Clinical interest is not budget ownership.

This week’s piece breaks down the adoption gap in healthtech, why pilots often mislead founders and investors, why workflow beats features, and what investors should diligence before believing commercial traction claims.

The next generation of healthtech winners will not only prove clinical value.

They will prove that the market can absorb it.